Insight Molecular Diagnostics (IMDX) Assets Average (2016 - 2026)

Insight Molecular Diagnostics has disclosed Assets Average across 11 years of filings, most recently posting $33.1 million for Q1 2026.

• Assets Average for Q1 2026 came in at $33.1 million, down 30.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.1 million (down 30.66% YoY), and the FY2025 annual result was $30.4 million, down 44.68% from the prior year.
• Assets Average came in at $33.1 million for Q1 2026 at Insight Molecular Diagnostics, down from $34.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $164.2 million in Q3 2022 to a low of $33.1 million in Q1 2026.
• The 5-year median for Assets Average is $72.9 million (2024), against an average of $84.3 million.
• Across the five-year window, Assets Average surged 65.56% in 2022 and sank 48.5% in 2023, its largest moves.
• Insight Molecular Diagnostics' Assets Average stood at $128.7 million in 2022, then sank by 39.22% to $78.2 million in 2023, then plunged by 32.71% to $52.6 million in 2024, then plunged by 33.81% to $34.8 million in 2025, then retreated by 5.04% to $33.1 million in 2026.
• The last three Assets Average figures came in at $33.1 million (Q1 2026), $34.8 million (Q4 2025), and $47.2 million (Q3 2025), per Business Quant data.